The Silent Epidemic of Liver Disease in the UK

A growing body of research has highlighted a disturbing link between diabetes, obesity, and liver disease. A new study reveals that diagnoses of metabolic dysfunction-associated steatotic liver disease (MASLD) have increased fivefold over the past decade, with nearly 283,000 people now affected.

The study analyzed GP records from nearly 12 million people in the UK between 2003 and 2022. The findings are stark: while just 0.02% of adults were diagnosed with MASLD in 2003 – equivalent to around 1,300 individuals – this number rose to 2.4% in 2022. This represents a staggering increase that has significant implications for the nation’s healthcare system.

The study found a disproportionate impact on certain groups, particularly people of south Asian ethnicity. These individuals were overrepresented among those diagnosed with MASLD, despite being less likely to have their liver scarring estimated using a blood test. This trend highlights existing health disparities in the UK and underscores the need for targeted interventions.

Researchers suggest that a simple blood test could be used to detect advanced fibrosis – the scarring of liver tissue that often precedes cirrhosis or liver failure. However, this raises questions about access to healthcare in the UK, where almost six million people live with diabetes – and nearly 1.3 million are undiagnosed.

The NHS data released earlier this year painted a bleak picture: over 30% of adults aged 16 and over were obese, while type 2 diabetes remained one of the leading causes of preventable morbidity. The study’s findings on MASLD diagnoses are therefore not surprising – but they do serve as a stark reminder of the need for systemic change.

The persistent diagnostic gap in the UK is a major concern. While there has been growing recognition of non-alcoholic fatty liver disease (NAFLD), researchers note that a significant number of cases remain undiagnosed. This gap is not just about detection – it’s also about treatment and prevention. With MASLD diagnoses doubling between 2012 and 2022, it’s clear that our current approach is failing.

The study’s authors call for more research into the causes of compounding health disparities among different ethnic groups. They are also correct in highlighting the need for urgent action: “more progress is needed to reach public health goals in this disease.” This is not just a matter of individual health – it’s also about economic sustainability.

Policymakers must prioritize targeted interventions that address the root causes of MASLD and NAFLD. This includes investing in public health campaigns, improving access to healthcare for marginalized communities, and supporting research into new treatments and prevention strategies.

Ultimately, the UK’s response to this crisis will be a test of its commitment to public health. Will we continue down the path of complacency, ignoring the growing epidemic of liver disease? Or will we take bold action to address the underlying causes of this crisis – and prioritize the health and well-being of our citizens? The choice is clear: it’s time for change.